Press Releases

Press Releases Presentations and Publications

ExCellThera to present at the 2023 Cell & Gene Meeting on the Mesa Conference

18.09.23

ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that David Millette, CEO, will present in person at the annual Cell & Gene Meeting on the Mesa conference to be held on October 10-12,…

UM171 cell therapy demonstrates improved outcomes compared to cord and matched unrelated donor peripheral blood transplants in real-world setting

12.12.22

MONTRÉAL, December 12, 2022 – ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today findings from a safety and efficacy retrospective analysis comparing outcomes of patients treated with ECT-001 (UM171-expanded) Cell Therapy in a…

ExCellThera announces completion of Phase 2 clinical trials for UM171-expanded cell therapy in high-risk blood cancers

15.11.22

MONTREAL, November 15, 2022 – ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today the completion of patient enrollment in its initial Phase 2 studies for high-risk leukemias and myelodysplastic syndromes (MDS).

ExCellThera announces 100th patient treated with UM171-expanded cell therapy

08.11.22

MONTREAL, November 8, 2022 – ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that its proprietary ECT-001 Cell Therapy has been administered to 100 patients. ECT-001 Cell Therapy is an investigational UM171-expanded cord…

ExCellThera announces oral presentation of new data on UM171-expanded cell therapy at the ASH Annual Meeting

04.11.22

ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that an abstract related to ExCellThera’s most advanced investigational drug, ECT-001 Cell Therapy, has been accepted for oral presentation at the upcoming 64th American Society…

ExCellThera to present at 2022 Cell & Gene Meeting on the Mesa Conference

20.09.22

ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that Co-CEO and COO David Millette will present in person at the annual Cell & Gene Meeting on the Mesa Conference to be held on…

ExCellThera announces submission of Drug Master File for UM171

17.06.22

MONTRÉAL, June 17, 2022 – ExCellThera Inc. (ExCellThera), an advanced clinical-stage biotechnology company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today that it has submitted…

ExCellThera to present at the 2022 Cell Therapy Transplant Canada Annual Meeting

13.06.22

MONTRÉAL, June 13, 2022 – ExCellThera Inc. (ExCellThera), an advanced clinical-stage biotechnology company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today that key findings will…

ExCellThera announces new publication showing its ECT-001 cell therapy improves transplant access for all patients

13.04.22

MONTREAL, April 13, 2022 – ExCellThera Inc. (ExCellThera), an advanced clinical-stage biotechnology company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today the publication of a…

ExCellThera to present at the Locust Walk Stem Cell TX Conference hosted in partnership with the Harvard Stem Cell Institute

07.04.22

MONTRÉAL, April 7, 2022 – ExCellThera Inc. (ExCellThera), an advanced clinical-stage biotechnology company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today that David Millette, Co-Chief…

ExCellThera announces new data to be presented at the EBMT 2022 annual meeting

15.03.22

MONTRÉAL, March 15, 2022 – ExCellThera Inc. (ExCellThera), a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today that new…

ExCellThera announces first patient treated in Phase I/II trial of ECT-001 cell therapy for pediatric patients with high risk blood cancer

10.03.22

MONTRÉAL, March 10, 2022 – ExCellThera Inc. (ExCellThera), a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today that the…

ExCellThera announces settlement of its patent infringement claims against Selleck Chemicals

21.12.21

MONTRÉAL, December 21, 2021 – ExCellThera Inc., a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today that it has…

ExCellThera announces data to be presented at the American Society of Hematology 2021 annual meeting

29.11.21

MONTRÉAL, November 29, 2021 – ExCellThera Inc., a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today that new data…

ExCellThera announces co-CEO management structure

09.11.21

MONTREAL, November 9, 2021 – ExCellThera Inc. (ExCellThera), a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today that its…

ExCellThera and Astellas enter into license for the use of molecule UM171 in the field of pluripotent stem cells

13.07.21

MONTREAL, July 13, 2021 – ExCellThera Inc. (ExCellThera), a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, today announced that it has entered into a licensing agreement with Astellas Pharma…

ExCellThera and Ossium Health announce a collaboration to advance their technologies and platforms to improve human health

21.04.21

MONTREAL, April 21, 2021 – ExCellThera Inc., a clinical-stage cell and molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, and Ossium Health, a therapeutics company harnessing the power of stem cell…

ExCellThera announces UM171 mechanism of action

07.01.21

MONTRÉAL, January 7, 2021 – ExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today the publication of new data describing the mechanism of action of UM171,…

ExCellThera receives Priority Medicines (PRIME) designation from European Medicines Agency for ECT-001 Cell Therapy

11.12.20

MONTRÉAL, December 11, 2020 – ExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that ECT-001 Cell Therapy has been granted PRIority MEdicines (PRIME) designation by…

ExCellThera receives Advanced Therapy Medicinal Product classification from European Medicines Agency for ECT-001 Cell Therapy

20.10.20

MONTRÉAL, October 20, 2020 – ExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that it has received Advanced Therapy Medicinal Product (ATMP) classification from the…

ExCellThera announces additional data to be presented at Cord Blood Association 2020 international congress

18.08.20

MONTREAL, August 18, 2020 – ExCellThera Inc., a clinical stage cell and molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that additional data from a Phase I/II clinical trial…

ExCellThera appoints Richard Cherney to its Board of Directors

15.07.20

MONTREAL, July 15, 2020 – ExCellThera Inc., a clinical stage cell and molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today the appointment of Richard Cherney to its Board of…

ExCellThera strengthens its Board of Directors and Scientific Advisory Board with new appointments

03.06.20

MONTRÉAL, JUNE 3, 2020 – ExCellThera Inc., a clinical-stage cell and molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today new appointments to its Board of Directors and Scientific Advisory…

ExCellThera receives grant from California Institute for Regenerative Medicine to fund clinical trial of ECT-001 Cell Therapy in sickle cell disease

19.05.20

MONTRÉAL, May 19, 2020 – ExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that it has received a grant from the California Institute for Regenerative…

ExCellThera announces EMA orphan medicinal product designation for ECT-001 Cell Therapy as treatment in haematopoietic stem cell transplantation

30.04.20

MONTREAL, April 30, 2020 — ExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that the European Medicines Agency has granted orphan medicinal product designation as…

ExCellThera announces preliminary Phase 2 data of ECT-001 Cell Therapy in high-risk leukemia and myelodysplasia

25.02.20

MONTREAL, February 25, 2020 – ExCellThera Inc., a clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, recently announced preliminary data from the Phase 2 trial of its ECT-001 Cell Therapy…

ExCellThera announces clinical data to be presented at the American Society of Hematology 2019 annual meeting

26.11.19

MONTRÉAL, November 26, 2019 – ExCellThera Inc., an advanced biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that data from a Phase I/II clinical trial using its lead technology, ECT-001,…

ExCellThera announces publication in The Lancet Haematology highlighting excellent clinical results of ECT-001 in patients with haematological malignancies

05.11.19

MONTRÉAL, November 5, 2019 – ExCellThera Inc., an advanced biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today the publication of full data from the first clinical trial using ECT-001 (single…

ExCellThera to present at 2019 Cell & Gene Meeting on the Mesa

11.09.19

MONTREAL, September 11, 2019 – ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that Guy Sauvageau, President and CEO, will present a company update…

ExCellThera’s lead technology, ECT-001, receives FDA Regenerative Medicine Advanced Therapy (RMAT) designation

23.04.19

MONTREAL, April 23, 2019 – ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that the U.S. Food and Drug Administration (FDA) has granted regenerative…

ExCellThera announces clearance by FDA and Health Canada for ECT-001 in new clinical trials in United States and Canada for the treatment of leukemia

25.03.19

MONTREAL, March 25, 2019 – ExCellThera Inc., a clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that its lead technology, ECT-001, will be used as part of two…

ExCellThera receives FDA orphan drug designation for ECT-001 for the prevention of graft-versus-host disease

17.12.18

MONTREAL, December 17, 2018 – ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that the U.S. Food and Drug Administration (FDA) has granted the ExCellThera’s lead solution,…

ExCellThera announces results of clinical trial using ECT-001 for blood cancers

04.12.18

MONTREAL, December 4, 2018 – ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, today announced results from the Phase I/II clinical trial using its lead technology, ECT-001, for allogeneic…

ExCellThera announces clinical trial results using ECT-001 to be presented at ASH 2018 annual meeting

08.11.18

MONTREAL, November 8, 2018 – ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, today announced that results from the Phase I/II clinical trial using its lead technology, ECT-001, for…

Final patient receives treatment in stem cell clinical trial for severe blood cancers

27.06.18

MONTREAL, June 27, 2018 – ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand blood stem cells for therapeutic use, announced today the close of its initial, 25-patient clinical trial for its lead technology, ECT-001. The final…

ECT-001 is basis of new clinical trial for multiple myeloma

14.05.18

(le français suit) MONTREAL, May 14, 2018 – ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand blood stem cells for therapeutic use, announced today that its lead platform, ECT-001, will be used as part of a…

ExCellThera announces appointment of Chief Financial and Legal Officer

22.03.18

(le français suit) MONTREAL, March 22, 2018 – ExCellThera Inc. announced today the appointment of David Millette as Chief Financial and Legal Officer effective April 3, 2018. Mr. Millette combines a solid background in finance and law, having practised in…

Scroll to view